CARBOPLATIN, CARBOPLATIN, Patritumab deruxtecan, PEMETREXED, CISPLATIN
U31402-A-U301
Phase 3 small_molecule active
Quick answer
CARBOPLATIN, CARBOPLATIN, Patritumab deruxtecan, PEMETREXED, CISPLATIN for Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) is a Phase 3 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo Europe GmbH
- Indication
- Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active